Skip to main content

Acquired Immunodeficiency Syndrome

21
Pipeline Programs
12
Companies
50
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
2
1
11
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 40 programs with unclassified modality

On Market (2)

Approved therapies currently available

Gilead Sciences
GENVOYAApproved
elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Gilead Sciences
Cytochrome P450 3A Inhibitor [EPC]oral2015
626M Part D
GSK
SELZENTRYApproved
maraviroc
GSK
CCR5 Co-receptor Antagonist [EPC]oral2016
9M Part D

Competitive Landscape

12 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
10 programs
2
2
1
cotrimoxazolePhase 4Small Molecule1 trial
VoriconazolePhase 3Small Molecule1 trial
immunoglobulinsPhase 31 trial
Interleukin-12Phase 11 trial
White blood cell infusionPhase 11 trial
+5 more programs
Active Trials
NCT00068978Completed200
NCT00051766Terminated200
NCT00001353Completed24Est. Mar 2002
+7 more trials
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
9 programs
1
D/C/F/TAFPHASE_21 trial
E/C/F/TDFPHASE_23 trials
E/C/F/TDFPHASE_2
EVG/COBI/FTC/TDFPHASE_2_31 trial
GENVOYA(COBI)PHASE_35 trials
+4 more programs
Active Trials
NCT01565850Completed153Est. Feb 2014
NCT02652624Completed472Est. Nov 2018
NCT01797445Completed872Est. Oct 2018
+9 more trials
GSK
GSKLONDON, United Kingdom
1 program
1
MaravirocPHASE_3
Kite Pharma
Kite PharmaCA - El Segundo
9 programs
2
1
6
COBIPhase 3
E/C/F/TDFPhase 3
E/C/F/TDFPhase 3
NNRTIPhase 3
PIPhase 3
+4 more programs
Human BioSciences
Human BioSciencesWV - Martinsburg
3 programs
1
1
immunoglobulinsPhase 3
Syngeneic LymphocytesPhase 1
Social Network Leader EndorsementN/A1 trial
Active Trials
NCT02639754Completed320Est. Jul 2024
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
MaravirocPhase 3
Pfizer
PfizerNEW YORK, NY
1 program
1
MaravirocPhase 31 trial
Active Trials
NCT00478231Completed209Est. Sep 2010
Genome & Company
Genome & CompanyKorea - Suwon
1 program
1
Syngeneic LymphocytesPhase 11 trial
Active Trials
NCT00001535Completed48Est. Mar 2002
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
4 programs
NevirapineN/A1 trial
NevirapinePHASE_31 trial
NevirapinePHASE_41 trial
nevirapinePHASE_41 trial
Active Trials
NCT02191215Completed442
NCT00144183Completed407Est. Jan 2007
NCT00144157Completed53Est. Jul 2006
+1 more trials
Becton Dickinson
Becton DickinsonFRANKLIN LAKES, NJ
1 program
BD FACS Presto SystemN/A1 trial
Active Trials
NCT02396355Completed583Est. May 2015
Relief Therapeutics
Relief TherapeuticsSwitzerland - Geneva
1 program
modified directly observed therapyN/A1 trial
Active Trials
NCT00272220Completed350Est. Jun 2006
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
epoetin alfaPHASE_25 trials
Active Trials
NCT00446602Withdrawn0Est. Aug 2009
NCT00269945Completed60Est. Jan 1989
NCT00269997Completed72Est. Jul 1990
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Gilead SciencesCOBI
Gilead SciencesCOBI
Allergy Therapeuticscotrimoxazole
Johnson & Johnsonepoetin alfa
Johnson & Johnsonepoetin alfa
Johnson & Johnsonepoetin alfa
Boehringer IngelheimNevirapine
Boehringer Ingelheimnevirapine
Johnson & Johnsonepoetin alfa
Johnson & Johnsonepoetin alfa
Johnson & Johnsonepoetin alfa
Johnson & Johnsonepoetin alfa
Gilead SciencesE/C/F/TDF
Gilead SciencesCOBI
Gilead SciencesE/C/F/TDF

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 13,801 patients across 50 trials

A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

Start: Aug 2024Est. completion: Mar 2034350 patients
Phase 4Recruiting

An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal

Start: Sep 2014Est. completion: Jan 201730 patients
Phase 4Completed

Safety of Cotrimoxazole in HIV- and HAART-exposed Infants

Start: Feb 2009Est. completion: Oct 2010222 patients
Phase 4Completed

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Start: Aug 2006Est. completion: Feb 200837 patients
Phase 4Terminated

A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia

Start: Jan 2006Est. completion: Sep 2009504 patients
Phase 4Completed

A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy

Start: Aug 2003Est. completion: Sep 2006110 patients
Phase 4Completed

Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV

Start: Jun 2003Est. completion: Jul 200653 patients
Phase 4Completed

Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults

Start: Apr 2002Est. completion: Oct 200310 patients
Phase 4Completed

EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

Start: Jun 2001Est. completion: May 2005292 patients
Phase 4Completed

Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency

Start: Feb 2001Est. completion: Jun 2003217 patients
Phase 4Terminated

A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Start: Nov 1999Est. completion: Apr 2004316 patients
Phase 4Completed

A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.

Est. completion: May 198817 patients
Phase 3Completed

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Start: Feb 2016Est. completion: Nov 2018472 patients
Phase 3Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Start: Dec 2015Est. completion: Mar 2018167 patients
Phase 3Completed

Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Start: Mar 2013Est. completion: Oct 2018872 patients
Phase 3Completed

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Start: Oct 2012Est. completion: Sep 2018583 patients
Phase 3Completed

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Start: Jan 2012Est. completion: Jul 201348 patients
Phase 3Completed

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Start: Dec 2011Est. completion: Dec 2014439 patients
Phase 3Completed

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Start: Nov 2011Est. completion: Dec 2014438 patients
Phase 3Completed

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Start: Oct 2011Est. completion: Jan 2016130 patients
Phase 3Completed

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Start: May 2011Est. completion: Feb 2015106 patients
Phase 3Completed

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Start: Apr 2010Est. completion: Apr 2015698 patients
Phase 3Completed

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Start: Jun 2008Est. completion: Jan 201025 patients
Phase 3Terminated

Multicenter, Safety Study Of Maraviroc

Start: Jul 2007Est. completion: Sep 2010209 patients
Phase 3Completed

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

Start: Sep 2006Est. completion: Feb 2008375 patients
Phase 3Completed

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Start: Mar 2006Est. completion: Jan 20172,098 patients
Phase 3Completed

An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation

Start: Feb 2005Est. completion: Dec 200551 patients
Phase 3Completed

The Duration Study

Start: Jun 2004Est. completion: Jul 20052 patients
Phase 3Terminated

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

Start: Feb 2004Est. completion: Oct 2004
Phase 3Terminated

Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Start: Feb 2004Est. completion: Oct 2004
Phase 3Terminated

Effect of Early High-dose Epoetin Alfa During Cardiac Arrest (Pilot Study)

Start: Nov 2003Est. completion: Jul 200420 patients
Phase 3Completed

Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)

Start: Sep 2003Est. completion: Jun 20061,460 patients
Phase 3Completed

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Start: Jun 2003Est. completion: May 200469 patients
Phase 3Completed

A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)

Start: Jan 2003Est. completion: Jan 2007407 patients
Phase 3Completed

Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer.

Start: Dec 2002Est. completion: Mar 200656 patients
Phase 3Completed

Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery

Start: Dec 2001Est. completion: Dec 200360 patients
Phase 3Completed

A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis Patients

Start: Feb 2000Est. completion: May 2003596 patients
Phase 3Completed

The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) Disease

Start: Nov 1999Est. completion: Apr 2003176 patients
Phase 3Completed

A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Start: Apr 1998Est. completion: May 2006680 patients
Phase 3Completed

A Safety and Efficacy Study for Epoetin Alfa in Pre-dialysis Subjects.

Start: Dec 1997Est. completion: Aug 2003172 patients
Phase 3Completed

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

Start: Aug 1997Est. completion: Aug 200010 patients
Phase 3Completed

Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

Start: Aug 1996Est. completion: Sep 1998375 patients
Phase 3Completed

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Start: May 1996Est. completion: Apr 19990
Phase 3Withdrawn

The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma

Start: Jan 1995Est. completion: Sep 1996156 patients
Phase 3Completed

A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.

Start: Apr 1993Est. completion: Aug 1994316 patients
Phase 3Completed

Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)

Start: Sep 1991Est. completion: Dec 1996
Phase 3Completed

A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.

Start: May 1989Est. completion: Jul 199177 patients
Phase 3Completed

A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.

Est. completion: Nov 1991112 patients
Phase 2/3Completed

A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)

Est. completion: Mar 199155 patients
Phase 2/3Completed

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Start: Jan 2014Est. completion: Mar 2027133 patients
Phase 2/3Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

11 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 13,801 patients
12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.